Osemitamab (FUT8-KO)

CAT: 0804-HY-P9991ASize: 1 EachDry Ice: NoHazardous: No
CAT#:0804-HY-P9991ASize:1 Each
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Osemitamab (FUT8-KO) is an anti-claudin-18.2 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study[1][2].
UNSPSC
12352203
Target
Gap Junction Protein
Related Pathways
Cytoskeleton
Applications
Cancer-programmed cell death
Field of Research
Cancer
Smiles
[Osemitamab(FUT8-KO)]
References & Citations
[1]Shen L, et al. Osemitamab in combination with capecitabine and oxaliplatin (CAPOX) as a first line treatment of advanced G/GEJ cancer: Updated data of cohort C from a phase I/IIa, multi-center study (TranStar102/TST001-1002) [J]. 2023.|[2]Park Soon Jae, et al. Pharmaceutical composition comprising human hyaluronidase PH20 variants for drug delivery system via subcutaneous injection. World Intellectual Property Organization, WO2023075506 A1. 2023-05-04.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported

Popular Products